Early observations and pilot data that first suggested a new direction
Standard neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy was the established approach for locally advanced rectal cancer, but adherence to adjuvant chemotherapy was poor (often <50%) due to postoperative morbidity and patient fatigue. The rationale for total neoadjuvant therapy was to deliver all systemic chemotherapy before surgery, when patients were better able to tolerate treatment, while potentially increasing pathologic complete response rates and facilitating organ preservation.
Proof
Landmark RCTs and pivotal trials that established the evidence base
The RAPIDO trial (2021) randomized 920 patients with high-risk locally advanced rectal cancer to experimental TNT (short-course radiotherapy followed by CAPOX/FOLFOX chemotherapy then surgery) versus standard care (long-course chemoradiation, surgery, and optional adjuvant chemotherapy). TNT significantly reduced disease-related treatment failure (23.7% vs 30.4%, p=0.019) and doubled pathologic complete response rates (28% vs 14%). PRODIGE 23 (2021) randomized 461 patients to neoadjuvant mFOLFIRINOX followed by chemoradiation and surgery versus standard chemoradiation and surgery. At 7-year follow-up, TNT improved disease-free survival (67.6% vs 62.5%) and overall survival, establishing mFOLFIRINOX-based TNT as a new standard.
Follow-up studies, subgroup analyses, and real-world validation
The OPRA trial demonstrated that TNT could be combined with a watch-and-wait strategy to achieve organ preservation. Among 324 patients with locally advanced rectal cancer treated with TNT, 46% achieved organ preservation without compromising disease-free survival. Long-term PRODIGE 23 data (7-year follow-up) confirmed a durable overall survival benefit with TNT (4.37 months RMST difference, p=0.033). These findings established TNT as both an oncologic and organ-preservation strategy.
Integration into clinical practice guidelines and recommendations
NCCN and ESMO guidelines incorporated TNT as a preferred approach for locally advanced rectal cancer based on RAPIDO and PRODIGE 23 data. The choice between short-course RT-based TNT (RAPIDO) and induction chemotherapy-based TNT (PRODIGE 23) depends on institutional preferences and patient factors.
NCCN
Total neoadjuvant therapy preferred for locally advanced (cT3-4 or N+) rectal cancer
ESMO
TNT recommended for high-risk locally advanced rectal cancer; either short-course RT-based or induction chemotherapy-based approaches acceptable
Now
Current standard of care and ongoing research directions
TNT has become the standard of care for locally advanced rectal cancer, supported by two concordant phase 3 trials. The integration of TNT with watch-and-wait strategies represents a transformative approach combining oncologic benefit with organ preservation. Active research areas include immunotherapy augmentation of TNT, ctDNA-guided treatment modification, optimal response assessment timing, and extending TNT to intermediate-risk patients. The question has evolved from whether TNT is effective to how to maximize complete response rates and identify patients who can safely avoid surgery.
What is total neoadjuvant therapy and how does it differ from standard treatment?+
TNT delivers all systemic chemotherapy before surgery rather than splitting it between neoadjuvant and adjuvant phases. The RAPIDO approach uses short-course RT followed by CAPOX/FOLFOX, while PRODIGE 23 uses induction mFOLFIRINOX followed by chemoradiation. Both approaches improve disease-free survival and double pathologic complete response rates (28% with RAPIDO, similar rates with PRODIGE 23) compared to standard chemoradiation alone.
Can patients avoid surgery entirely with TNT?+
The OPRA trial demonstrated that 46% of patients treated with TNT achieved organ preservation through a watch-and-wait strategy without compromising disease-free survival. Patients who achieve a complete clinical response enter structured surveillance, and most who experience regrowth can be salvaged with surgery. TNT combined with watch-and-wait represents the most promising organ preservation strategy in rectal cancer to date.
